A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barretts oesophagus

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 11-12, 2010, Pages 1332-1342

  Boger, P C ^a   Turner, D ^b   Roderick, P ^b   Patel, P ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DYSPLASIA; ESOPHAGUS DISEASE; ESOPHAGUS DYSPLASIA; ESOPHAGUS RESECTION; HEALTH CARE COST; HUMAN; MORTALITY; PERIOPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RECURRENCE RISK; SENSITIVITY ANALYSIS; TREATMENT FAILURE; UNITED KINGDOM;

BARRETT ESOPHAGUS; CATHETER ABLATION; COST-BENEFIT ANALYSIS; ESOPHAGECTOMY; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS;

EID: 78449273514     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04450.x     Document Type: Article

References (57)

1. Corder AP, Jones RH, Sadler GH, Daniels P, Johnson CD,. Heartburn, oesophagitis and Barretts oesophagus in self-medicating patients in general practice. Br J Clin Pract 1996; 50: 245 - 8.
2. Csendes A, Smok G, Burdiles P, et al. Prevalence of Barretts esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus 2000; 13: 5 - 11.
3. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barretts esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825 - 31.
4. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF,. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287 - 9.
5. Jankowski JA, Provenzale D, Moayyedi P,. Esophageal adenocarcinoma arising from Barretts metaplasia has regional variations in the west. Gastroenterology 2002; 122: 588 - 90.
6. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R,. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45: 931 - 91.
7. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 2009; 10: 351 - 69.
8. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P,. Incidence of esophageal adenocarcinoma in patients with Barretts esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008; 67: 394 - 8.
9. Watson A, Heading RC, Shepherd NA,. Guidelines for the diagnosis and management of Barretts columnar lined oesophagus. A report of the working party of the British Society of Gastroenterology, August 2005. Available at:.
10. Palser T, Cromwell D, Meulen J, et al. The National Oesophago-Gastric Cancer Audit. An audit of the care received by people with Oesophago-gastric Cancer in England and Wales. First Annual Report 2009. London: NHS Information Centre, 2009.
11. Lagergren P, Avery KN, Hughes R, et al. Health-related quality of life among patients cured by surgery for esophageal cancer. Cancer 2007; 110: 686 - 93.
12. National Institute for Health and Clinical Excellence. Photodynamic Therapy for Barretts Oesophagus: Guidance. National Institute for Health and Clinical Excellence, June 2010. Available at:.
13. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barretts high-grade dysplasia. Gastrointest Endosc 2007; 66: 460 - 8.
14. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barretts esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005; 62: 488 - 98.
15. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barretts esophagus with dysplasia. N Engl J Med 2009; 360: 2277 - 88.
16. Chang LC, Oelschlager BK, Quiroga E, et al. Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barretts esophagus. J Gastrointest Surg 2006; 10: 341 - 6.
17. Zaninotto G, Parenti AR, Ruol A, Costantini M, Merigliano S, Ancona E,. Oesophageal resection for high-grade dysplasia in Barretts oesophagus. Br J Surg 2000; 87: 1102 - 5.
18. Headrick JR, Nichols FC, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002; 73: 1697 - 702.
19. Nguyen NT, Schauer P, Luketich JD,. Minimally invasive esophagectomy for Barretts esophagus with high-grade dysplasia. Surgery 2000; 127: 284 - 90.
20. Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999; 230: 433 - 8.
21. Patti MG, Arcerito M, Feo CV, et al. Barretts esophagus: a surgical disease. J Gastrointest Surg 1999; 3: 397 - 404.
22. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barretts esophagus. Gastroenterology 2007; 132: 1226 - 33.
23. Reed MF, Tolis G, Edil BH, et al. Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg 2005; 79: 1110 - 5.
24. Sujendran V, Sica G, Warren B, Maynard N,. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barretts oesophagus. Eur J Cardiothorac Surg 2005; 28: 763 - 6.
25. Tseng EE, Wu TT, Yeo CJ, Heitmiller RF,. Barretts esophagus with high grade dysplasia: surgical results and long-term outcome - an update. J Gastrointest Surg 2003; 7: 164 - 71.
26. Williams VA, Watson TJ, Herbella FA, et al. Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome. J Gastrointest Surg 2007; 11: 1589 - 97.
27. Office of National Statistics. Deaths: age and sex. Health Stat Q Winter 2008; 40: 57 table 6.1.
28. NICE Methodology Working Party. Guide to the Methods of Technology Appraisal [Document on the Internet]. National Institute for Health and Clinical Excellence, June 2008. Available at:.
29. Shenfine J, McNamee P, Steen N, Bond J, Griffin SM,. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol Assess 2005; 9: 1 - 121.
30. Gondrie JJ, Pouw RE, Sondermeijer CMT, et al. Stepwise circumferential and focal ablation of Barretts esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008; 40: 359 - 69.
31. Overholt BF, Panjehpour M, Halberg DL,. Photodynamic therapy for Barretts esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58: 183 - 8.
32. Briggs AH, Claxton K, Sculpher MJ,. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
33. Pouw RE, Gondrie JJ, Sondermeijer CM, et al. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg 2008; 12: 1627 - 36.
34. Sharma VK, Jae Kim H, Das A, Wells CD, Nguyen CC, Fleischer DE,. Circumferential and focal ablation of Barretts esophagus containing dysplasia. Am J Gastroenterol 2009; 104: 310 - 7.
35. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE,. Dysplasia and cancer in a large multicenter cohort of patients with Barretts esophagus. Clin Gastroenterol Hepatol 2006; 4: 566 - 72.
36. Garside R, Pitt M, Somerville M, et al. Surveillance of Barretts oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006; 10: 1 - 142.
37. Portale G, Hagen JA, Peters JH, et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 2006; 202: 588 - 96.
38. Quine MA, Bell GD, McCloy RF, et al. Prospective audit of perforation rates following upper gastrointestinal endoscopy in two regions of England. Br J Surg 1995; 82: 530 - 3.
39. Drummond MF, Sculpher MJ, Torrance GW, OBrien BJ, Stoddart GL,. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005.
40. De Boer AGEM, Stalmeier PFM, Sprangers MAG, et al. Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients utilities and treatment preferences. Br J Cancer 2002; 86: 851 - 7.
41. Hur C, Wittenberg E, Nishioka NS, et al. Quality of life in patients with various Barretts esophagus associated health states. Health Qual Life Outcomes 2006; 4: 45 - 50.
42. Department of Health. Tariff Information: Confirmation of Payment by Results (PbR) Arrangements for 2009/10 [Document on the Internet]. Department of Health, Feb 2009. Available at:.
43. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005; 14: 339 - 47.
44. Lothgren M, Zethraeus N,. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623 - 30.
45. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ,. A cost-utility analysis of ablative therapy for Barretts esophagus. Gastroenterology 2009; 136: 2101 - 14.
46. Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barretts esophagus that contains high-grade dysplasia: a U.S Multicenter Registry. Gastrointest Endosc 2008; 68: 35 - 40.
47. Gondrie JJ, Pouw RE, Sondermeijer CMT, et al. Effective treatment of early Barretts neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008; 40: 370 - 9.
48. Shaheen NJ, Wolfsen HC, Hawes RH, et al. Impact of Barretts esophagus containing dysplasia on patient quality of life: Interim results of a randomized, sham-controlled trial of radio-frequency ablation (AIM dysplasia trial). Gastroenterology 2008; 134: A323.
49. Gemmill EH, McCulloch P,. Systematic review of minimally invasive resection for gastro-oesophageal cancer. Br J Surg 2007; 94: 1461 - 7.
50. National Institute for Health and Clinical Excellence. Barretts Oesophagus - Ablative Therapy: Full Guideline for Consultation (Draft). National Institute for Health and Clinical Excellence, March 2010. Available at:.
51. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P,. What is the best management strategy for high grade dysplasia in Barretts oesophagus? A cost effectiveness analysis. Gut 2004; 53: 1736 - 44.
52. Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD,. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barretts esophagus. Gastrointest Endosc 2004; 60: 739 - 56.
53. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barretts esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120: 1630 - 9.
54. Dar MS, Goldblum JR, Rice TW, Falk GW,. Can extent of high grade dysplasia in Barretts oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut 2003; 52: 486 - 9.
55. Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, Siewert JR,. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005; 242: 566 - 73.
56. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barretts esophagus. Gastroenterology 2009; 137: 815 - 23.
57. Sibbald B, Roland M,. Understanding controlled trials. Why are randomised controlled trials important? BMJ 1998; 316: 201.